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Several lines of evidence have suggested that iron is critical for Mycobacterium tuberculosis growth in macrophages. Macrophage
iron loading in patients with African iron overload increases the risk of tuberculosis (TB) and may worsen TB outcome.
Likewise, macrophage iron loading may contribute to an increased predisposition toward TB in HIV infection. Human genetic
disorders or variations may increase the risk of TB or worsen its outcome through macrophage iron loading, including the
haptoglobin 2-2 phenotype, NRAMP1 polymorphisms (at least in Africans and Asians), and possibly ferroportin 1 mutations,
but not HFE hemochromatosis. Thus, the host’s iron status may be an important yet underevaluated factor in TB prevention
and therapy and in TB vaccine design.
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In this review of the relationship between
tuberculosis and iron, we wish to bridge
biological and clinical issues, emphasizing
human conditions that might result in
macrophage iron loading. The degree of
evidence from clinical studies is rated by
grades: 1 (randomized controlled), 2 (non-
randomized controlled), and 3 (uncon-
trolled studies, descriptive studies, and
expert opinion).
We searched in Medline, without date
restriction, for the terms “mycobacterium,”
“tuberculosis,” “iron,” and “macrophage”
and searched for them in interaction with
“immune reaction”; “immunology”; “Th1,
Th2, cytokines”; “African iron overload”;
“malaria”; “plasmodium”; “hemozoin”;
“tobacco”; “smoking”; “alcohol”; “etha-
nol”; “alcoholism”; “HIV”; “AIDS”; “ge-
netics”; “hemochromatosis”; “HFE”;
“haptoglobin”; “NRAMP1”; “SLC11A1”;
“p-aminosalicylic acid”; “isoniazid”;
“ethambutol”; “tuberculosis vaccine”;
and “BCG.” Because of space limitations,
only those articles considered by all au-
thors to be most relevant were retained.
MACROPHAGE IRON
HOMEOSTASIS
As shown in figure 1 and as reviewed by
others [1], macrophages engulf and di-
gest senescent erythrocytes, degrade heme,
and, thus, accumulate iron into the cy-
tosol. Cytosolic iron may be partly incor-
porated into ferritin, but normally most
of it egresses the macrophage to be bound
by plasma transferrin for delivery to bone-
marrow erythroid precursors. Macrophage
iron export is mediated by ferroportin 1
(also termed “SLC40A1”), the receptor for
hepcidin, a peptide secreted by the liver
in response to inflammation or excess iron
[2]. The hepcidin-ferroportin 1 complex
is internalized and degraded in lysosomes,
locking iron inside macrophages (as well
as enterocytes) [2]. Erythrophagocytosis
and subsequent iron export via ferropor-
tin 1 constitutes the major iron flux in-
volving macrophages. Iron also enters
macrophages via the transferrin-transfer-
rin receptor (TfR) pathway [1], the bind-
ing of ferric lactoferrin (hololactoferrin)
to lactoferrin receptors [3], and the bind-
ing of hemoglobin-haptoglobin (Hp) to
the macrophage CD163 receptor during
hemolysis [4]; these pathways may assume
greater importance depending on the spe-
cific macrophage location and function-
al specialization. Inflammation induces
macrophage iron retention, as observed
in patients with inflammation, whose
blood monocytes show down-regulated
ferroportin 1 expression that correlates
with increased ferritin levels and mirrors
increased urinary hepcidin concentra-
tions (used as surrogate for plasma hep-
cidin) [5].
ACQUISITION OF IRON
BY MYCOBACTERIUM
TUBERCULOSIS
Importance of iron acquisition. As
confirmed in patient alveolar macro-
phages, M. tuberculosis resides within the
macrophage phagosome and prevents
phagosome-lysosome fusion by an unclear
mechanism [6, 7]. The M. tuberculosis–
containing phagosome has early endoso-
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Figure 1. Schematic representation of a Mycobacterium tuberculosis (MTb)–infected macrophage and its iron metabolism. MTb resides in an early
phagosome, whose maturation to the late phagosome and phagolysosome stages is blocked and whose acidification is limited. Macrophage iron
sources are: (1) heme-bound iron from red blood cells (RBCs, main source; the presence of SLC11A1/NRAMP1 within the RBC vacuole is still speculative)
and from the hemoglobin-haptoglobin complex, taken up via the hemoglobin scavenger receptor CD163; and (2) iron bound to transferrin and lactoferrin.
On release into the cytoplasm, iron can be incorporated into proteins, including the iron-storage protein ferritin, and its presence can be sensed by
iron regulatory proteins (not shown). Iron is exported from the cell via SLC40A1 (ferroportin 1), at least when the serum concentration of hepcidin is
low to normal; when serum hepcidin is high (as occurs in iron excess or in the presence of inflammation), hepcidin binds to ferroportin 1, the complex
is internalized, and iron export is inhibited, resulting in the iron-retention characteristic of inflammation. Binding of iron-bound lactoferrin to its cellular
receptor and subsequent iron release are ill defined. Serum iron-bound transferrin binds to the transferrin receptor on the cell surface, and the complex
is internalized in the early endosome, where low pH separates iron from the complex, allowing the iron-free complex to recycle to the cell surface
and iron to be released into the cytoplasm via SLC11A2 (DMT1). Within its phagosome, MTb can capture iron either from cytoplasmic sources
(represented by the central rectangle) or from the transferrin/transferrin receptor complex by interacting with the early endosome. These captures are
made possible by a dual mycobacterial siderophore system made of mycobactins. These consist in a water-soluble carboxymycobactin T, which is
thought to vehicle iron to a lipophilic mycobactin T associated with the MTb cell wall. Some evidence suggests that phagosomal iron can be pumped
out via the SLC11A1 (NRAMP1) efflux pump.
mal characteristics, interacts with early en-
dosomes, and does not acidify below pH
6.3–6.5 [6, 7]. M. tuberculosis perceives the
phagosome as a low-iron environment [8,
9]: hence the importance of iron-acqui-
sition strategies in the face of the host’s
iron-withholding mechanisms [9, 10]. Iron
limitation induces at least 35 M. tuber-
culosis genes, including mbtA–J, which
encode enzymes involved in siderophore
biosynthesis, but represses bfrA, which
encodes an iron-storing bacterioferritin
[8]. Consistent with the concept of iron
restriction during immune control of
M. tuberculosis replication, mbtB mRNA
levels increase and bfrB mRNA levels
decrease several weeks after infection in
mice [11, 12].
Tools used. Salicylate-derived M.
tuberculosis siderophores, termed “my-
cobactins,” are composed of 2 entities:
hydrophilic mycobactin T (carboxymyco-
bactin) and the more lipophilic M. tuber-
culosis cell wall–associated mycobactin T,
which appears to transfer iron captured
by hydrophilic mycobactin across the my-
cobacterial cell wall [13]. An M. tuber-
culosis strain with a deleted mbtB gene
has interrupted mycobactin synthesis, im-
paired intraphagosomal iron acquisition,
and retarded growth within THP-1 cells
[14, 15]. The product of another M. tu-
berculosis gene, ideR, represses mbt ex-
pression in an iron-dependent manner but
activates bfrA [16, 17]. Two other genes,
irtA and irtB (for iron-regulated trans-
porters A and B), encode enzymes that
possibly translocate Fe-carboxymycobac-
tin into the mycobacterial cytoplasm in-
dependently of mycobactin [18].
Host iron sources. M. tuberculosis scav-
enges iron from the host-cell transferrin-
iron acquisition pathway [6] (figure 1).
Mycobactins are able to extract iron from
exogenous holotransferrin [6, 19]. Phago-
somes containing live M. tuberculosis
interact with early endosomes to which
holotransferrin traffics (figure 1) [6]. M.
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Table 1. Influence of alterations in iron status on the growth of
Mycobacterium tuberculosis (MTb) both in vitro and in vivo.
Growth, conditions
MTb growth
[references]
Enhanced Inhibited
In vitro growth
Growth in broth or serum
Iron salts [24–27]
Serum transferrin [29]
Desferrioxamine [26]
Silybin [27]
Phytosiderophore [33]
Growth in the macrophage
Murine macrophage
Iron salts [28]
Lactoferrin [26]
Anti-TfR antibody [26]
Siderophore-deficient MTb mutant [14]
Human macrophage
Iron salts [27, 28] [23]
Gallium-transferrin [34]
irtAB mutation of MTb [18]
In vivo growth (murine infection)
Iron enrichment of drinking water [26]
Parenteral iron [29–32]
Desferrioxamine [26, 30]
b2m KO mice [26]
b2m KO mice treated with (vs. untreated
b2m KO mice)
Intranasal lactoferrin [26]
Desferrioxamine [26]
irtAB mutant of MTb [18]
NOTE. b2m, b2-microglobulin; KO, knockout; TfR, transferrin-transferrin receptor.
tuberculosis within the macrophage phago-
some is able to concentrate more iron
from transferrin than the nonpathogenic
M. smegmatis [15]. Mycobactins are also
able to acquire iron from cytoplasmic
pools supplied by holotransferrin [19] and
from hololactoferrin, which is more avail-
able at the pulmonary infectious site than
is holotransferrin [20, 21]. In a recent study
[22], gallium-loaded lipophilic mycobac-
tin J from M. paratuberculosis (a sur-
rogate for ferric-mycobactin J and struc-
turally close to mycobactin T) was added
exogenously to macrophages and was
found to (1) equilibrate throughout in-
fected and even surrounding cells and dis-
tribute between macrophage aqueous and
membrane domains; (2) scavenge both
holotransferrin-released and cytoplasmic
iron; and (3) be recruited as Fe-mycobac-
tin to lipid droplets delivered through lipid
trafficking to Escherichia coli–contain-
ing phagosomes. Although these results
are interesting, the exogenous addition of
mycobactin does not mimic the in vivo sit-
uation, nor does an E. coli–infected phago-
some mimic an M. tuberculosis–infected
phagosome. In summary, M. tuberculosis
appears to evade host defense by pre-
venting phagosome acidification and ly-
sosome fusion, to acquire iron from host
endosomal holotransferrin, and—if con-
firmed—to utilize host lipid trafficking
for the delivery of additional iron by
mycobactin.
Effect of modifying iron status on M.
tuberculosis growth. Adding iron ex-
perimentally has always—with a single ex-
ception [23]—resulted in enhanced M. tu-
berculosis growth, both in vitro (axenic
medium or macrophage infection) [24–
28] and in mice [29–32] (table 1). Fur-
thermore, M. tuberculosis growth is re-
duced by interrupting iron availability,
whether by (1) treatment with an exoge-
nous iron chelator, such as deferoxamine
[26, 30], sylibin [27], or a phytosidero-
phore [33]; (2) exposure to the endogenous
iron chelators apo-transferrin [29] and
apo-lactoferrin [26]; (3) the addition of
an anti-TfR antibody to M. tuberculosis–
infected macrophages [27]; or (4) incu-
bation with gallium salts or gallium trans-
ferrin that occupy iron pathways with a
metal that cannot be utilized by M. tu-
berculosis [34]. Genetic studies have con-
firmed the importance of iron for M. tu-
berculosis. First, as mentioned previously,
a mutant defective in mycobactin synthe-
sis has decreased growth in macrophages
[14]. Similarly, an irtAB mutant compro-
mised in the utilization of iron from Fe-
carboxymycobactin has also been shown
to have defective growth [18]. Finally, b2-
microglobulin knockout mice, given that
they are iron overloaded, are more sus-
ceptible to tuberculosis (TB) than are
control mice [26]. However, these mice
are of questionable relevance for study-
ing the relationship between TB and
iron, because they also have several T
cell deficiencies [35].
HOST DEFENSE AGAINST M.
TUBERCULOSIS
As reviewed by others [36–38], defense
against TB involves immune recognition
by macrophages and dendritic cells, which
leads to tumor necrosis factor (TNF)–a
production and cooperative interaction
with T cells, mainly CD4+ T lymphocytes
and NK cells. The resulting Th1 type pro-
inflammatory reaction includes interleu-
kin (IL)–18, IL-12, interferon (IFN)–g,
and IL-1b production and is responsible
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for killing or controlling M. tuberculosis.
Effector mechanisms involve reactive ox-
ygen and nitrogen intermediates and ap-
optosis. Antiinflammatory cytokines such
as IL-4, IL-10, and transforming growth
factor–b, the latter 2 of which are pro-
duced by regulatory T (Treg) cells, suppress
Th1 type responses and interfere with ef-
fector T cell activation.
Of M. tuberculosis–infected humans,
5%–10% develop clinical TB, whereas the
majority develop latent infection charac-
terized by quiescent M. tuberculosis with a
strong Th1 and a possibly suppressed Th2
cytokine response [38]. Clinical TB is as-
sociated with a mixed Th1/Th2 response
and Th2 dominance [38], and therapeutic
recovery from TB usually involves restored
Th1 dominance over Th2 [39].
EFFECT OF CYTOKINES
ON MACROPHAGE IRON
STATUS
IFN-g, which is pivotal for protection
against TB, also influences cellular iron
status. Indeed, IFN-g activation of human
monocytes down-regulates TfR numbers
on the cell surface [40] and the rate of
macrophage iron acquisition from holo-
transferrin [19], and it decreases iron avail-
ability to intracellular microorganisms
that utilize transferrin iron, such as Le-
gionella pneumophila [40] and M. tuber-
culosis, as discussed above. M. tuberculosis
remains able, at least in vitro, to access
other iron sources, despite the IFN-g–in-
duced limitation in macrophage iron ac-
quisition [19]. Macrophage M. tuberculosis
infection does not subvert this IFN-g–in-
duced decrease in TfR expression [19, 41].
In contrast to classical macrophage ac-
tivation by bacterial products or IFN-g,
alternative macrophage activation by Th2
cytokines has 2 potential implications
for macrophage iron status. First, during
experimental TB, alternatively activated
mouse macrophages express the gene en-
coding arginase-1 [41]. Arginase-1 com-
petition with inducible nitric oxide syn-
thase (iNOS) for l-arginine results in
decreased NO production and, hence,
possibly less iron efflux [42] and more
iron being available to M. tuberculosis.
Whether the differential expression of ar-
ginase-1 versus iNOS applies to humans
is unclear. Second, alternative activation
of uninfected macrophages results in in-
creased expression of both TfR and CD163,
resulting in increased TfR-related and
CD163-mediated iron acquisition [41, 43].
Furthermore, in a comparative gene-ex-
pression study of M. tuberculosis–infected
murine macrophages activated by either
IL-4 or IFN-g, IL-4 led to increases in both
host TfR expression and M. tuberculosis
iron availability as manifested by de-
creased mycobactin and increased bacte-
rioferritin synthesis, whereas IFN-g was
associated with opposite findings [41].
Whether these interesting experimental
results apply to human M. tuberculosis in-
fection is speculative. The fact that serum
ferritin levels increased in a dose-depen-
dent manner during recombinant human
IL-10 treatment of patients with Crohn
disease (evidence grade 1) [44] is consis-
tent with the concept that immunosup-
pressive cytokines increase macrophage
iron availability.
EFFECT ON TB
OF CONDITIONS THAT
MAY AUGMENT
RETICULOENDOTHELIAL
IRON STORES
In some conditions, reticuloendothelial
iron loading originates from the alimen-
tary tract, the respiratory route, or he-
molysis, whereas, in others, it results from
chronic inflammation. The administration
of iron-dextran to rats results in bron-
choalveolar macrophage iron loading [45].
Hence, it is conceivable that human iron-
loading conditions might enhance M. tu-
berculosis growth in alveolar macrophages.
Iron loading affects the immune system in
a way that resembles alternative mac-
rophage activation. When erythropoie-
tin-treated patients undergoing hemodi-
alysis were randomized to receive or not
receive intravenous iron, those receiving
iron developed lower TNF-a but higher
IL-4 serum concentrations (evidence grade
1) [46]. In volunteers receiving 120 mg of
oral iron daily for 7 days, IL-4 serum levels
increased modestly but significantly [47].
Some clinical conditions characterized
by generalized or local reticuloendothelial
iron loading are possibly associated with
TB. In African iron overload and in HIV/
AIDS, the available evidence suggests a
pathophysiological role of iron loading
that increases the risk of TB or worsens
its outcome. In other conditions that in-
crease the risk of TB and/or worsen its
outcome (e.g., tobacco smoking and al-
coholism), there is some degree of iron
loading, but its pathogenetic role is hy-
pothetical; in human malaria, another con-
dition with increased macrophage iron,
the association with TB, is conjectural.
Although inconclusive, data on tobacco
smoking, alcoholism, and malaria are
presented as basis of future research.
African iron overload. Iron overload
of both macrophages and hepatocytes is
common in sub-Saharan African popu-
lations drinking a traditional beverage of
high iron content that is brewed in non-
galvanized steel containers. In addition to
high dietary iron, a non-HFE genetic de-
fect may be implicated in iron loading
[48]. African iron overload was first de-
scribed in autopsies performed in the
1920s on black Africans whose cause of
death was recorded, and hepatic, splenic,
and lymph-node iron was graded on a
scale of 1–5. When these data were rean-
alyzed in the 1990s, splenic (macrophage)
iron was the variable most significantly as-
sociated with death from TB—the odds
of death from TB were 16.9-fold higher
in persons with the highest, compared
with the 2 lowest, grades of splenic iron
(evidence grade 2) [49]. In a prospective
study of the relationship between pul-
monary TB and increased dietary iron
(lifetime consumption of traditional beer)
among 98 Zimbabwean patients with pul-
monary TB and 98 control subjects, in-
creased dietary iron was associated with
a 3.5-fold increase in the estimated odds
of developing pulmonary TB and with
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a trend toward higher mortality among
the patients with pulmonary TB (evidence
grade 2) [50].
HIV/AIDS. The HIV epidemic dra-
matically fuels the coexisting TB epidemic.
Macrophage iron loading in the setting of
HIV may be due to blood transfusion or
to HIV- and opportunistic infection–in-
duced inflammation [51], which would be
expected to lead to hepcidin production
and macrophage iron trapping. HIV may
also contribute to macrophage iron load-
ing by its Nef protein, which interacts with
HFE, the protein mutated in classical he-
reditary hemochromatosis, and markedly
decreases its expression on the surface of
macrophages. The net effect of this inter-
action is to increase macrophage iron and
ferritin content [52]. Macrophage iron
loading during HIV infection may in-
crease oxidative stress and lower intracel-
lular glutathione levels, impairing the anti-
TB defense. Indeed, (nitroso-)glutathione
inhibits M. tuberculosis growth in vitro,
whereas the glutathione precursor N-ace-
tyl cysteine improves control of intracel-
lular M. tuberculosis cultured in blood
from HIV-infected patients [53]. Clinical
studies of the adverse influence of high
iron stores on the outcome of HIV infec-
tion have been reviewed elsewhere [54].
One retrospective study of bone-marrow
macrophage iron grades in HIV-seropos-
itive patients found significantly more fre-
quent TB in patients with high, compared
with low or normal, macrophage iron
grades (evidence grade 3) [55]. The impact
of HIV-related macrophage iron loading
on TB requires more investigation.
Tobacco smoking. Tobacco smoking
is a major risk factor for pulmonary but
not extrapulmonary TB infection and
death, which implicates a local airborne
insult [56]. A parasympathetic antiinflam-
matory pathway has been identified, where-
by activation of macrophage a7 nicotinic
acetylcholine receptors in bronchoalveolar
macrophages reduces the synthesis and re-
lease of TNF-a, IL-1, and IL-6 [57]. Be-
cause nicotine is an agonist of these re-
ceptors, tobacco smoking should inhibit
alveolar macrophage TNF-a release, im-
pairing the formation of appropriate M.
tuberculosis–containing granulomas. To-
bacco smoking may also favor TB by iron
loading alveolar macrophages, given that
smoking 1 pack of cigarettes is equivalent
to inhaling 1.1 mg of iron [58]. Iron levels
in alveolar macrophages are 2-fold higher
in asymptomatic smokers and 4.6–7-fold
higher in symptomatic smokers than in
nonsmokers. Proof that tobacco smoking
increases the risk of TB by loading the
alveolar macrophages with iron is lacking
at present.
Alcoholism. In a cross-sectional study
in humans [59], alcoholism was the stron-
gest predictor of TB in tobacco smokers,
with an adjusted odds ratio of 7.4 (evi-
dence grade 2). Alcoholism may result in
alimentary iron loading because ethanol
metabolism down-regulates hepcidin ex-
pression [60]. Among 8839 individuals
who did not consume alcohol or who had
consumed !1, 1–2, or 12 daily alcoholic
drinks during the preceding year, serum
transferrin saturation and ferritin levels
were significantly higher in consumers of
12 daily alcoholic drinks, compared with
nonconsumers, after adjustment for po-
tential confounders [61]. After 2 weeks of
alcohol consumption, mice had decreased
lymphocyte proliferation and IFN-g pro-
duction, smaller granulomas, and higher
M. tuberculosis lung burdens than control
mice [62]. At the bronchoalveolar level,
chronic alcoholism suppresses Th1 and in-
duces Treg cells responses [63], potentially
enhancing the risk of TB, but it is un-
known whether human alcoholism may
favor TB by inducing alveolar macrophage
iron loading. In one study, chronic alco-
hol exposure of rats did not increase iron
levels in alveolar macrophages, in agree-
ment with alcohol-induced down-regula-
tion of hepcidin, but the sample size was
limited [64].
Malaria. In most reports, a Th1-bi-
ased response clears an uncomplicated
acute human Plasmodium falciparum in-
fection [65]. Malaria suppresses the im-
mune response to both parasite and non-
parasite antigens, probably because of
macrophage accumulation of hemozoin, a
hematin (ferri-protoporphyrin IX) poly-
mer derived from hemoglobin ingested by
intraerythrocytic plasmodia [66]. Hemo-
zoin-fed human monocyte–derived mac-
rophages produce IL-10 in a dose-depen-
dent manner [67] and show impaired
differentiation to mature dendritic cells
[67], and T cells activated by these den-
dritic cells lack effector functions [68]. M.
tuberculosis–infected mice coinfected later
with P. yoelii have higher organ M. tuber-
culosis burdens than mice infected only
with M. tuberculosis and have higher mor-
tality than mice infected only with M. tu-
berculosis or P. yoelii. Hemozoin-related
lung and liver pigmentation is stronger in
coinfected mice than in those infected
only with plasmodium species, which sug-
gests that there is more malarial hemol-
ysis-induced iron loading that favors M.
tuberculosis growth in coinfected mice
[69]. At present, it is unclear whether ma-
laria affects the development or outcome
of human TB.
IRON-RELATED GENES
AND HUMAN TUBERCULOSIS
Hereditary iron overload. In classical
hereditary hemochromatosis caused by
homozygosity for the C282Y mutation of
HFE, alimentary iron overabsorption re-
sults in iron loading of liver, heart, and
pancreas parenchymal cells, whereas mac-
rophages are relatively iron deficient. In
M. tuberculosis–infected macrophages from
patients with hemochromatosis, intrapha-
gosomal M. tuberculosis acquires less iron
from holotransferrin and is 50% growth-
retarded, compared with that in normal
macrophages [19, 21]. Studies to confirm
whether patients with hemochromatosis
have a lower risk of TB have not been
reported. M. tuberculosis has been hy-
pothesized to exert a selective pressure re-
sponsible for a high prevalence of HFE
mutations in certain populations (evidence
grade 3) [70]. By contrast, ferroportin 1
mutations often result in macrophage iron
loading [71]. Whether they may increase
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the risk of TB is unknown. Salmonella en-
terica growth is reduced by macrophage
ferroportin 1 expression and increased by
its hepcidin-induced down-regulation[72],
which is compatible with the suggestion
that a ferroportin 1 mutation also might
increase TB susceptibility.
Hp. Binding of hemoglobin-Hp to
the monocyte/macrophage CD163 results
in internalization of heme and, eventually,
to heme degradation and IL-10 secretion
[73]. There are 3 Hp phenotypes: Hp 1-
1, Hp 1-2, and Hp 2-2. Multimeric Hp 2-
2, which has a 10-fold higher CD136 af-
finity than Hp 1-1, may result in greater
macrophage iron acquisition [4] and in-
creased serum markers of iron loading, as
has been observed in some but not all
studies (reviewed in [74]), as well as more
macrophage IL-10 production. In the pre-
viously mentioned study of Zimbabwean
patients with pulmonary TB and control
subjects [50], the Hp phenotype did not
modulate TB susceptibility, but it did af-
fect treatment outcome; the odds of death
were 6.1-fold higher in patients with TB
carrying Hp 2-2, compared with those car-
rying Hp 1-1 [75]. It is uncertain whether
this worse TB outcome in individuals car-
rying Hp 2-2 relates to differences in iron
status.
NRAMP1. NRAMP1, the gene prod-
uct of NRAMP1 (SLC11A1), is principally
expressed in the membranes of late en-
dosomes, phagosomes, and lysosomes of
macrophages. In mice, NRAMP1 activates
an early microbicidal mechanism that pro-
vides resistance to several intracellular mi-
croorganisms, including M. avium and M.
bovis (bacille Calmette-Gue´rin [BCG]) but
not M. tuberculosis. A G169D substitution
renders NRAMP1 nonfunctional, causing
murine susceptibility to these infections.
NRAMP1 transports divalent cations (pu-
tatively iron) across the phagosomal mem-
brane, but opposing views exist on the flux
direction: either Fe2+ influx into the bac-
terium-containing phagosome causes bac-
terial killing by forming reactive oxygen
species [76], or, because macrophages
without functional NADPH oxidase have
their resistance unaffected [77], Fe2+ efflux
restricts bacterial growth by iron depri-
vation [77, 78]. The latter view is gain-
ing more experimental support (figure
1) [79]. The G169D mutation in human
NRAMP1 has never been found, but there
are several NRAMP1 polymorphisms in
the noncoding human gene regions.
Fourteen studies examining the rela-
tionship between human NRAMP1 poly-
morphisms and TB susceptibility were an-
alyzed in a meta-analysis that involved
2460 case patients and 3227 control sub-
jects and covered the 4 most investigated
NRAMP1 polymorphisms [80]. The odds
ratio of TB with the 3′ untranslated region
(UTR) variant was 1.33, that with the
D543N variant was 1.67, that with the
INT4 variant was 1.14, and that with the
5′(GT)n variants was 1.32, compared with
the corresponding common alleles. Poly-
morphisms at these 4 loci significantly in-
creased the risk of pulmonary TB in Af-
ricans (except the 3′ UTR) and in Asians
(except INT4) but not in white persons,
whose numbers were low (evidence grade
2). More data are needed about the di-
rection of the NRAMP1-associated iron
flux and the effect of NRAMP1 polymor-
phisms on TB susceptibility.
ANTITUBERCULAR THERAPY
AND IRON
p-aminosalicylic acid inhibits the conver-
sion of salicylate to (carboxy-)mycobactin
and therefore targets M. tuberculosis iron
acquisition [13]. The prodrug isoniazid
needs conversion to an active form that
inhibits mycolic acid biosynthesis. This
conversion requires the heme-containing
catalase peroxidase, which is encoded by
the M. tuberculosis katG gene and protects
M. tuberculosis against oxidative damage
[81]. In a study of the effect of experi-
mental iron loading on the therapeutic ef-
ficacy of isoniazid in murine high-inoc-
ulum TB infection [32], the bactericidal
activity of isoniazid was significantly
reduced in iron-loaded compared with
normal-iron mice, because of either the
growth-promoting or immunological ef-
fects of iron or the massive oxidative stress
overwhelming the katG-associated protec-
tion against reactive oxygen species.
ANTITUBERCULAR
VACCINATION AND IRON
BCG vaccination is of low efficacy in
persons in developing tropical and sub-
tropical areas, who also face helminth
infections, environmental mycobacteria,
malaria, HIV, and malnutrition—condi-
tions that may suppress Th1 and enhance
Th2/Treg cell responses [38]. It seems pos-
sible that an increased macrophage iron
burden may be one of the mechanisms
exacerbating immune dysregulation and
BCG vaccine failure. We suggest that iron
status should be taken into account in fur-
ther studies of anti–M. tuberculosis vac-
cines. For instance, one could (1) compare
results of vaccinating animals fed an iron-
poor versus iron-enriched diet and (2) test
the administration of apolactoferrin to-
gether with new TB vaccines, given that
apolactoferrin coadministration enhances
delayed-type hypersensitivity toward BCG
in mice [82] and increases the efficacy
of BCG in protecting mice against viru-
lent M. tuberculosis [83]. It is uncertain
whether this beneficial lactoferrin ef-
fect relates to iron binding, immuno-
logical effects, or antibacterial activity
of its breakdown peptide, lactoferricin.
RESEARCH PROSPECTS
In view of the critical importance of iron
in TB pathogenesis, research might be di-
rected at examining the effect of manip-
ulating several stages of the iron pathways
of the host and the invading organism: (1)
the quantity of iron entering the host via
the alimentary, parenteral, and respiratory
routes; (2) the amount of hepcidin cir-
culating in the host; (3) the function of
ferroportin 1, the hepcidin receptor, at the
host macrophage membrane; (4) the di-
rection of iron flux by NRAMP1 at the
host phagosomal membrane; (5) host
phagosomal maturation and acidification;
(6) mycobactin synthesis by M. tubercu-
losis; and (7) the ferric mycobactin trans-
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port pathway of M. tuberculosis. Further-
more, research on M. tuberculosis and iron
may result in spin-offs into unrelated
fields. For example, iron-free mycobactin
reversibly blocks the in vitro growth of
vascular smooth-muscle cells because its
iron-chelating properties block redox-
modulated signaling pathways and sever-
al enzymes. One clinical situation where
blocking the proliferation of these cells
might be desirable is the prevention of
coronary restenosis after coronary balloon
angioplasty. Intramural application of my-
cobactin shortly after coronary balloon in-
jury, tested in a porcine model, halved the
injury score and reduced neointima thick-
ness [84]. Results in humans are awaited.
CONCLUSION
Trousseau reported in 1872 [85] that pa-
tients recovering from active TB had a re-
lapse if they received iron-rich supple-
ments, and he warned against their use.
The relationship between iron and TB is
now strengthened thanks to the elucida-
tion of the M. tuberculosis genome, ad-
vances in immunology, and clinical study
results. Drugs that target mycobacterial
iron-acquisition pathways or host path-
ways that affect iron availability for M.
tuberculosis are worth developing and test-
ing for anti-TB activity. The role of iron
should be taken into account in future
vaccine studies.
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